Advanced searches left 3/3

Metastatic neuroendocrine carcinoma - Europe PMC

Summarized by Plex Scholar
Last Updated: 25 January 2022

* If you want to update the article please login/register

Partial response of metastatic cardia neuroendocrine carcinoma with the combined therapy involving PD-1 blockade after failed multi-line chemotherapies: a case report and literature review.

Cardia neuroendocrine cancer, a rare benign tumor, is a rare benign tumor. The treatment regimens mainly refer to the small-cell lung cancer diagnosis and treatment guidelines, although there is no such guidelines specifically for neuroendocrine cancer. There has never been any evidence of the use of albumin pactisol plus sintilimab in refractory cardia neuroendocrine carcinoma. By gastroscopy and pathological findings, a 68-year-old man was diagnosed with belching without apparent reasons and was diagnosed with refractory cardia NEC. This article described a case where a 68-year-old man was diagnosed with belching without apparent causes. After the patient's receiving this therapy regimen, the signs of dysphagia absorption disappeared, and neuron-specific enolase change trends were reduced. This is the first case report that shows that the albumin paclitaxel plus sintilimab has had good success after failing to achieve multi-line therapy of cardia NEC.

Source link: https://europepmc.org/article/MED/34620744

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions